The aim of this trial was to assess the relative patient acceptability of t
wo transdermal oestradiol patches used in treatment of oestrogen deficiency
in postmenopausal women.
Thirty-five hysterectomised postmenopausal women with no previous experienc
e of transdermal oestradiol delivery systems received treatment with: eithe
r once-weekly drug-in-adhesive (DIA) patches or twice-weekly reservoir patc
hes for 4 weeks, and were then switched to the alternative treatment for a
further 4 weeks. At the end of the study, the patients completed a question
naire to assess their relative preference for a number of characteristics o
f the 2 transdermal systems and, where possible, their preference for trans
dermal compared with! oral hormone replacement therapy.
Thirty-one patients completed the study; four withdrew during treatment wit
h the reservoir patch. The DIA patch was preferred for being 'easiest to re
member to apply' by 80% of patients (p < 0.01), 'easiest to open' and 'easi
est to apply' by 68% (p = 0.025), and as having 'best cosmetic appearance'
by 65% (p = 0.05) and 'best overall skin adhesion' by 61% (p < 0.01). While
10% of patients rated the reservoir patch as 'least irritating to the skin
' (p = 0.03), only one patient found this patch 'most comfortable to wear'
(p < 0.01). The DHA patch was selected by 87% of patients as their preferre
d treatment overall (p = 0.001). Ninety-one per cent of 22 responding patie
nts were at least as confident of treatment with transdermal patches as wit
h oral hormone replacement therapy (p = 0.006) and 74% of 27 responders pre
ferred transdermal to oral treatment (p = 0.004).
The DIA patch appears to be more acceptable to patients than the reservoir
patch as a transdermal oestradiol delivery system for the treatment of post
menopausal oestrogen deficiency. Characteristics of the DIA patch which may
account for improved patient acceptance include ease of remembering once-w
eekly patch application, improved cosmetic appearance and comfort, and bett
er adhesion.